NCT02440334View on ClinicalTrials.gov

Two and Three Dimensional Contrast-enhanced Ultrasound for Screening of Renal Cell Carcinoma Recurrence Following Cryoablation

PHASE2CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

April 23, 2015

Primary Completion Date

December 31, 2017

Study Completion Date

June 21, 2018

Conditions
Renal Cell Carcinoma
Interventions
DRUG

Optison

Optison is an ultrasound contrast agent. The agent is a blood pooling agent administered via catheter and provides improved ultrasound visualization of the vasculature.

Trial Locations (1)

19107

Thomas Jefferson University, Philadelphia

All Listed Sponsors
lead

Thomas Jefferson University

OTHER

NCT02440334 - Two and Three Dimensional Contrast-enhanced Ultrasound for Screening of Renal Cell Carcinoma Recurrence Following Cryoablation | Biotech Hunter | Biotech Hunter